Valneva and Serum Institute end chikungunya vaccine partnership
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
The approval introduces a needle-free alternative to injectable GLP-1 therapies
India’s pharmaceutical sector stands at a pivotal inflection point
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Subscribe To Our Newsletter & Stay Updated